Managing chronic thromboembolic pulmonary hypertension: Pharmacological treatment options

European Respiratory Review

Volumn 18, Issue 111, 2009, Pages 24-28

  Lang, I M ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chronic thromboembolic pulmonary hypertension; Drug therapy; Review

Indexed keywords

BOSENTAN; ILOPROST; SILDENAFIL; VASODILATOR AGENT;

ALGORITHM; ARTICLE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ENDARTERECTOMY; HEART RIGHT VENTRICLE FAILURE; HISTOPATHOLOGY; HUMAN; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; PATHOGENESIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; VENOUS THROMBOEMBOLISM;

CHRONIC DISEASE; HUMANS; HYPERTENSION, PULMONARY; PULMONARY EMBOLISM;

EID: 61649096898     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00011110     Document Type: Article

References (40)

1. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Circulation 2006; 113: 2011-2020.
2. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12, 5S-12S.
3. Simonneau G, Delcroix M, Mayer E, Lang IM, Pepke-Zaba J. First international registry on chronic thromboembolic pulmonary hypertension (CTEPH). Eur Respir J 2008; 32: Suppl. 52, 174s-175s.
4. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975; 17: 259-270.
5. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345: 1465-1472.
6. Becattini C, Agnelli G, Pesavento R, et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest 2006; 130: 172-175.
7. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257-2264.
8. Lang IM. Chronic thromboembolic pulmonary hypertension - not so rare after all. N Engl J Med 2004; 350: 2236-2238.
9. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003; 76: 1457-1462.
10. Mayer E,KlepetkoW.Techniquesand outcomes of pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006; 3: 589-593.
11. Mellemkjaer S, Ilkjaer LB, Klaaborg KE, et al. Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Ten years experience in Denmark. Scand Cardiovasc J 2006; 40: 49-53.
12. Dartevelle P, Fadel E, Mussot S, et al. Chronic thrombo- embolic pulmonary hypertension. Eur Respir J 2004; 23: 637-648.
13. Peacock A, Simonneau G, Rubin L. Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006; 3: 608-614.
14. Kim NH. Assessment of operability in chronic thrombo- embolic pulmonary hypertension. Proc Am Thorac Soc 2006; 3: 584-588.
15. Hartz RS, Byrne JG, Levitsky S, Park J, Rich S. Predictors of mortality in pulmonary thromboendarterectomy. Ann Thorac Surg 1996; 62: 1255-1259.
16. Archibald CJ, Auger WR, Fedullo PF, et al. Long-term outcome after pulmonary thromboendarterectomy. Am J Respir Crit Care Med 1999; 160: 523-528.
17. Lewczuk J, Piszko P, Jagas J, et al. Prognostic factors in medically treated patients with chronic pulmonary embolism. Chest 2001; 119: 818-823.
18. Azarian R, Wartski M, Collignon MA, et al. Lung perfusion scans and hemodynamics in acute and chronic pulmonary embolism. J Nucl Med 1997; 38: 980-983.
19. Bonderman D, Jakowitsch J, Redwan B, et al. Role for staphylococci in misguided thrombus resolution of chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol 2008; 28: 678-684.
20. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 1993; 103: 685-692.
21. Egermayer P, Peacock AJ. Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. Eur Respir J 2000; 15: 440-448.
22. Ryu JH, Olson EJ, Pellikka PA. Clinical recognition of pulmonary embolism: problem of unrecognized and asymptomatic cases. Mayo Clin Proc 1998; 73: 873-879.
23. Meignan M, Rosso J, Gauthier H, et al. Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch Intern Med 2000; 160: 159-164.
24. Lang IM, Marsh JJ, Olman MA, Moser KM, Schleef RR. Parallel analysis of tissue-type plasminogen activator and type 1 plasminogen activator inhibitor in plasma and endothelial cells derived from patients with chronic pulmonary thromboemboli. Circulation 1994; 90: 706-712.
25. Lang IM, Marsh JJ, Olman MA, Moser KM, Loskutoff DJ, Schleef RR. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation 1994; 89: 2715-2721.
26. Bonderman D, Jakowitsch J, Adlbrecht C, et al. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 2005; 93: 512-516.
27. Jais X, Ioos V, Jardim C, et al. Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax 2005; 60: 1031-1034.
28. Bonderman D, Wilkens H, Wakounig S, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 2008; [Epub ahead of print PMID: 18799507].
29. Bresser P, Pepke-Zaba J, Jais X, Humbert M, Hoeper MM. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. Proc Am Thorac Soc 2006; 3: 594-600.
30. Skoro-Sajer N, Hack N, Sadushi R, et al. Abstract 2305: Pulmonary vascular reactivity and prognosis in patients with chronic thromboembolic pulmonary hypertension. Circulation 2007; 116: II503-II504.
31. Galie N, Kim NH. Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006; 3: 571-576.
32. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351:1425-1436.
33. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329.
34. Suntharalingam J, Treacy CM, Doughty NJ, et al. Long-term use of sildenafil in inoperable chronic thrombo-embolic pulmonary hypertension. Chest 2008; 134: 229-236.
35. Jais X, Ghofrani A, Hoeper MM, et al. Bosentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): a randomized, placebo-controlled trial - BENEFiT. Am J Respir Crit Care Med 2007; 175: A896.
36. Jais X, Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52: 2127-2134.
37. 2-induced acute renal failure. Toxicol Appl Pharmacol 1998; 152: 315-326.
38. Bauer M, Wilkens H, Langer F, Schneider SO, Lausberg H, Schafers HJ. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002; 105: 1034-1036.
39. Kim H, Yung GL, Marsh JJ, et al. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J 2000; 15: 640-648.
40. Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic thrombo- embolic pulmonary hypertension. Am J Respir Crit Care Med 2008; 177: 1122-1127.